Clinical Scorecard: Analysis of Carfilzomib Usage and Patient Outcomes in Relapsed or Refractory Multiple Myeloma: Insights from Real-World Data
At a Glance
Category
Detail
Condition
Relapsed or Refractory Multiple Myeloma (RRMM)
Key Mechanisms
Proteasome inhibition via selective and irreversible binding leading to tumor cell death
Target Population
Patients aged 18-70 with RRMM treated in second or subsequent lines of therapy
Care Setting
Academic and community cancer clinics across the United States
Key Highlights
Carfilzomib demonstrates improved progression-free and overall survival compared to bortezomib in RRMM.
Multiple dosing schedules exist: twice-weekly (27, 56 mg/m2) and once-weekly (56, 70 mg/m2), with varying efficacy and toxicity profiles.
Real-world data from 280 US clinics analyzed prescribing patterns and outcomes to identify optimal dosing strategies.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical and laboratory criteria for multiple myeloma with assessment of cytogenetic risk per IMWG criteria.
Management
Use carfilzomib in combination with dexamethasone and other agents (IMiDs, CD38 mAbs) for RRMM.
Consider dosing schedules: K56-2x, K27-2x, K70-1x, and K56-1x based on patient tolerance and prior evidence.
Monitor for cardiac and renal toxicities associated with carfilzomib.
Monitoring & Follow-up
Regular assessment of renal function via serum creatinine.
Monitor for neuropathy, cardiac events, and other adverse effects during therapy.
Track response rates and progression-free survival to guide therapy adjustments.
Risks
Cardiac and renal toxicities are notable with carfilzomib use.
Neuropathy risk is lower than with bortezomib but still requires monitoring.
Dose adjustments may be necessary to minimize toxicity.
Patient & Prescribing Data
Adults aged 18-70 with RRMM receiving second or later line carfilzomib-containing regimens.
Initial dosing typically starts at 20 mg/m2 with escalation; real-world dosing varies widely with no consensus on optimal schedule. Once-weekly 70 mg/m2 showed improved PFS over 27 mg/m2 twice-weekly in trials, but comparisons with other dosing regimens remain unestablished.
Clinical Best Practices
Start carfilzomib at 20 mg/m2 with dose escalation based on tolerance.
Choose dosing schedule (once-weekly vs twice-weekly) considering efficacy, toxicity, and patient convenience.
Combine carfilzomib with dexamethasone and other agents (IMiDs, CD38 mAbs) for enhanced outcomes.
Monitor renal function and cardiac status closely during treatment.
Adjust dosing promptly in response to adverse events to maintain therapy adherence.
by Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur
